Home > Riviste > Minerva Gastroenterology > Fascicoli precedenti > Minerva Gastroenterology 2022 September;68(3) > Minerva Gastroenterology 2022 September;68(3):346-7

ULTIMO FASCICOLO
 

JOURNAL TOOLS

Opzioni di pubblicazione
eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo
Share

 

LETTERS TO THE EDITOR   Free accessfree

Minerva Gastroenterology 2022 September;68(3):346-7

DOI: 10.23736/S2724-5985.21.02921-1

Copyright © 2021 EDIZIONI MINERVA MEDICA

lingua: Inglese

Safety of bevacizumab combined with chemotherapy in the treatment of recurrent ovarian cancer and its effect on adverse reactions and digestive function

Ping JIA 1, Suwen CHANG 2, Yanan ZHANG 3, Ruifang TANG 4, Xing LIU 5, Yingjia XU 6, Aimin LIANG 7

1 Department of Obstetrics and Gynecology, Xiangyang N.1 People’s Hospital Affiliated Hospital of Hubei University of Medicine, Xiangyang, China; 2 Department of Gynecology, Yantai Yuhuangding Hospital, Yantai, China; 3 Department of Nursing, People’s Hospital of Xiangzhou District, Xiangyang, China; 4 Dongfeng Emergency Station, Xiangyang Emergency Center, Xiangyang, China; 5 Department of Neurosurgery, Xiangyang N.1 People’s Hospital Affiliated Hospital of Hubei University of Medicine, Xiangyang, China; 6 Department of Nursing, Institute of Medicine and Nursing, Hubei University of Medicine, Shiyan, China; 7 UCC, Xiangyang N.1 People’s Affiliated Hospital of Hubei University of Medicine, Xiangyang, China



inizio pagina